Skip to content
Valvena
-
Valneva terminates Asia vaccine partnership with Serum Institute of India
The collaboration aimed to support the distribution of Valneva’s single-dose vaccine, Ixchiq, in low- and middle-income countries (LMICs) across Asia.
-
Valneva to close Nantes facility, centralizing R&D in Vienna following lower sales forecast
The closure announcement follows Valneva’s financial results for the first nine months of 2025, which revealed mixed performance.